COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00392431
Recruitment Status : Completed
First Posted : October 26, 2006
Last Update Posted : March 22, 2007
Netherlands Heart Foundation
Information provided by:
University Medical Center Groningen

Brief Summary:
Our hypothesis is that episodic amiodarone treatment (i.e. amiodarone treatment 1 month prior until 1 month after cardioversion) is associated with a lower morbidity and a higher quality of life compared to continuous prophylactic amiodarone treatment while atrial fibrillation is still effectively suppressed. The latter means that at the end of the study permanent atrial fibrillation is prevented in comparable percentage of patients (70%) in both treatment strategies. However, this will be accomplished at the cost of a higher number of electrical cardioversions (2-3) in the episodic treatment group compared to the continuous treatment group.

Condition or disease Intervention/treatment Phase
Persistant Atrial Fibrillation Drug: amiodarone Not Applicable

Detailed Description:

Primary objective

To determine differences in adverse event rates between patients with persistent atrial fibrillation who are randomized to episodic amiodarone treatment (EAT) strategy and patients who are randomized to continuous amiodarone treatment (CAT) strategy, while atrial fibrillation is still effectively suppressed.

Adverse events can be related to:

  1. amiodarone use
  2. atrial fibrillation itself or underlying heart disease.

Secondary objective

To determine differences in quality of life between patients with persistent atrial fibrillation who are randomized to the EAT strategy and patients who are randomized to the CAT strategy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Continuous Versus Episodic Prophylactic Treatment With Oral Amiodarone for the Prevention of Permanent Atrial Fibrillation: a Randomized Study on Morbidity and Quality of Life
Study Start Date : January 2003
Actual Study Completion Date : March 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Adverse events related to amiodarone use and/or atrial fibrillation itself or underlying heart disease

Secondary Outcome Measures :
  1. Quality of life
  2. Number of patients with permanent AF at the end of the study

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Symptomatic persistent atrial fibrillation for at least 48 hours- 1 year (present episode).
  2. Older than 18 years of age.
  3. Ventricular rate during AF > 75 beats per minute, documented on rest-ECG without rate control.
  4. At least two weeks of oral anticoagulation therapy before screening.
  5. Written informed consent.

Exclusion criteria:

  1. Contra indications for amiodarone (severe chronic obstructive pulmonary disease or QTc > 440ms).
  2. History of relapse of AF during adequate amiodarone treatment (i.e. adequate amiodarone and desethylamiodarone plasma levels).
  3. Concomitant treatment with class I or III antiarrhythmic drugs. Amiodarone should not have been used during the last 3 months.
  4. Other (non) cardiac QT prolonging drugs (if not possible to discontinue).
  5. First episode of persistent atrial fibrillation.
  6. More than three relapses of persistent atrial fibrillation necessitating electrical cardioversion during the last three years.
  7. Known sick sinus syndrome.
  8. History of second or third degree AV conduction disturbances.
  9. Intraventricular conduction disturbances (QRS> 140ms).
  10. Pacemaker treatment.
  11. Hemodynamically significant valvular disease.
  12. Patients with heart failure with symptoms according to NYHA class III or IV.
  13. Unstable angina pectoris.
  14. Recent myocardial infarction (< 3 months).
  15. PTCA, CABG, other cardiac surgery or major non-cardiac surgery within the last three months.
  16. History of hyperthyroidism or hypothyroidism.
  17. Serious pulmonary, hepatic, haematological, metabolic, renal, gastrointestinal, CNS or psychiatric disease.
  18. Pregnant and non-pregnant women who are pre-menopausal and are not practising an acceptable method of contraception.
  19. Treatment with any other investigational agent.
  20. Presence of any disease that is likely to shorten life expectancy to < 1 year.
  21. Any condition that in the opinion of the investigator would jeopardise the evaluation of efficacy or safety or be associated with poor adherence to the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00392431

Layout table for location information
University Medical Center Groningen
Groningen, Netherlands, 9700RB
Sponsors and Collaborators
University Medical Center Groningen
Netherlands Heart Foundation
Layout table for investigator information
Principal Investigator: Isabelle C Van Gelder, MD University Medical Center Groningen
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00392431    
Other Study ID Numbers: 2000B133
First Posted: October 26, 2006    Key Record Dates
Last Update Posted: March 22, 2007
Last Verified: March 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Anti-Arrhythmia Agents
Vasodilator Agents
Potassium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Sodium Channel Blockers
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP3A Inhibitors